LEGN Legend Biotech Corporation

Biotech Analyst Ratings

Latest News

1. 18 May 2022 Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

   • Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel)
   • Updated data from Cohorts A and B of the CARTITUDE-2 study evaluating cilta-cel in earlier lines of multiple myeloma treatment will also be featured

   Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that eight company-sponsored abstracts were accepted at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's…

   View Full Article
2. 09 May 2022 Legend Biotech Appoints Lori Macomber as Chief Financial Officer

   Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO and Chief Executive Officer (CEO) since September 2020. Dr. Huang will continue to serve as CEO of Legend Biotech.

   "Lori is a highly valued leader and strategic thought partner that has been instrumental in building the company's finance organization," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Lori possesses deep financial and accounting expertise and…

   View Full Article
3. 06 May 2022 Legend Biotech Announces Participation in Upcoming Investor Conferences

   Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

   Event: Bank of America Securities 2022 Healthcare Conference
   Presentation Date & Time: Wednesday, May 11, 2022 at 5:20pm PT / 8:20pm ET
   Location: Las Vegas, Nevada
   Presenter: Ying Huang, Ph.D., CEO

   Event: Jefferies Global Healthcare Conference
   Presentation Date & Time: Wednesday, June 8, 2022 at 1:00pm PT / 4:00pm ET
   Location: New York, New York
   Presenter: Ying Huang, Ph.D., CEO

   Event: Goldman Sachs Annual Global Healthcare Conference
   Presentation Date & Time: Wednesday, June 15…

   View Full Article
4. 21 April 2022 Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

   Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the achievement of a $50 million milestone under its collaboration agreement with Janssen Biotech, Inc. (Janssen) for ciltacabtagene autoleucel (cilta-cel), now marketed in the United States under the brand name CARVYKTI™. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.

   Legend Biotech entered into the agreement with Janssen to develop, manufacture and commercialize cilta-cel for the treatment of multiple myeloma. Under the agreement, Legend Biotech received an upfront payment of $350…

   View Full Article
5. 01 April 2022 Legend Biotech Announces Appointment of Global Head of Research and Early Development

   Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development.

   Dr. Guowei Fang is an accomplished scientist and pharmaceutical research and development leader who brings a wealth of experience in oncology and immunology to the role. Dr. Fang comes to Legend Biotech from Zymeworks Inc, where he served as senior vice president of Research and oversaw the development of novel platforms and a portfolio of multi-functional biologics and antibody drug conjugates. Prior to that, Dr. Fang led discovery…

   View Full Article